Dr. West Discusses Afatinib and Cetuximab Combination in NSCLC

onclivetv has 407 videos Subscribe Here

Description: H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the results from the phase II trial combining two therapies, afatinib and cetuximab, in patients with T790M mutated as a mechanism of resistance in non-small cell lung cancer (NSCLC). He describes that the benefit not only helped T790M patients but also those without the mutation.
Shared By : onclivetv
Posted on : 07/07/11
Added : 6 years ago

More From onclivetv

Nothing found.